Capricor Therapeutics recently joined PPMD for a community webinar to provide a current update on the company’s Biologics License Application (BLA) seeking full approval of deramiocel (CAP-1002), Capricor’s novel cell therapy for the treatment of cardiomyopathy in patients diagnosed with Duchenne.

Disclaimer: This webinar program is intended solely to provide information to the public. The views and opinions expressed as part of this webinar program do not necessarily state or reflect those of Parent Project Muscular Dystrophy (PPMD).